Alpha Cognition Secures U.S. Patent for ALPHA-1062 in Traumatic Brain Injury, Expanding Pipeline Potential
Alpha Cognition Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, has announced a significant milestone in its intellectual property strategy. The company revealed that the United States Patent and Trademark Office (USPTO) has granted a new U.S. patent covering the use of its lead therapeutic candidate, ALPHA-1062, for the treatment of traumatic brain injury (TBI). This development marks an important step forward in broadening the therapeutic scope of the company’s pipeline beyond Alzheimer’s disease.
The newly issued patent (U.S. Patent No. 12,589,099), granted on March 31, 2026, provides protection for methods of treating both confirmed and suspected traumatic brain injury using ALPHA-1062. With coverage extending through 2045, the patent significantly strengthens Alpha Cognition’s long-term commercial and scientific strategy.
Expanding the Intellectual Property Portfolio
The issuance of this patent enhances Alpha Cognition’s already growing intellectual property portfolio. The company has been actively building a robust patent estate around its key assets, including ALPHA-1062 and ZUNVEYL®, its Alzheimer’s-focused therapeutic.
By securing protection for the application of ALPHA-1062 in traumatic brain injury, Alpha Cognition not only diversifies the potential indications for its lead candidate but also reinforces its competitive positioning in the neuroscience space. Intellectual property protection is a critical component for biopharmaceutical companies, ensuring exclusivity, attracting investment, and supporting long-term commercialization strategies.
This newly granted patent complements existing protections for ALPHA-1062 and aligns with the company’s broader vision of maximizing the lifecycle value of its drug candidates. With exclusivity now projected to extend into the mid-2040s, Alpha Cognition is well-positioned to pursue sustained development and commercialization opportunities.
ALPHA-1062: A Versatile Therapeutic Candidate
ALPHA-1062 has been primarily developed as a treatment for Alzheimer’s disease, a neurodegenerative condition with significant global impact. However, the mechanism of action underlying ALPHA-1062 has shown promise beyond Alzheimer’s, particularly in conditions involving neurological injury and dysfunction.
The new patent highlights the therapeutic potential of ALPHA-1062 in treating traumatic brain injury, a condition characterized by sudden damage to the brain caused by external force. TBI can result from falls, vehicle accidents, sports injuries, or combat-related trauma and often leads to long-term cognitive, physical, and emotional impairments.
By extending the application of ALPHA-1062 into TBI, Alpha Cognition is leveraging the drug’s pharmacological properties to address a broader spectrum of neurological disorders. This strategic expansion reflects a growing trend in drug development, where therapies initially designed for one indication are evaluated for additional uses based on shared biological pathways.
Addressing a Significant Unmet Medical Need
Traumatic brain injury remains a major public health challenge worldwide. Despite its high prevalence and significant burden on patients, families, and healthcare systems, there are currently no approved pharmacological treatments specifically targeting TBI.
Patients with TBI often rely on supportive care and rehabilitation, with limited options to directly address the underlying neurological damage. This gap in treatment options underscores the urgent need for innovative therapies that can improve outcomes and quality of life for affected individuals.
Alpha Cognition estimates that the total addressable market for TBI therapies could reach approximately $14 billion, reflecting the scale of the unmet need and the potential commercial opportunity. By advancing ALPHA-1062 into this indication, the company aims to position itself as a pioneer in a largely untapped therapeutic area.
Strategic Implications for Alpha Cognition
The patent issuance represents more than just a legal milestone—it is a strategic inflection point for Alpha Cognition. By expanding the potential applications of ALPHA-1062, the company is effectively broadening its pipeline without the need to develop entirely new compounds from scratch.
This approach offers several advantages:
- Reduced development risk: Leveraging existing clinical and preclinical data for ALPHA-1062 can streamline development timelines.
- Cost efficiency: Expanding indications for a single molecule can be more economical than initiating new drug discovery programs.
- Enhanced valuation: A broader pipeline increases the company’s attractiveness to investors and potential partners.
Moreover, the alignment of patent protection through 2045 ensures that Alpha Cognition has a long runway to develop, test, and commercialize ALPHA-1062 across multiple indications.
Leadership Perspective
Michael McFadden, Chief Executive Officer of Alpha Cognition, emphasized the importance of this milestone in the company’s evolution. According to McFadden, the patent not only highlights the innovative nature of ALPHA-1062 but also reinforces the long-term value of the company’s broader portfolio, including ZUNVEYL®.
He noted that expanding into traumatic brain injury represents a strategic move to address a large and underserved patient population. With no currently approved therapies for TBI, the opportunity to establish a first-mover advantage is particularly compelling.
McFadden also highlighted the company’s disciplined approach to portfolio expansion, focusing on maximizing the value of existing assets while maintaining a commitment to delivering meaningful outcomes for patients and stakeholders alike.
First-Mover Opportunity in TBI
One of the most notable aspects of this development is the potential for Alpha Cognition to become a first mover in the TBI treatment space. In pharmaceutical markets, being first to market with an effective therapy can provide significant competitive advantages, including:
- Strong brand recognition
- Early establishment of clinical guidelines
- Market exclusivity benefits
- Enhanced pricing power
Given the absence of approved treatments for TBI, ALPHA-1062 could play a transformative role if clinical studies demonstrate efficacy and safety in this indication. The newly granted patent lays the groundwork for such development efforts, providing both protection and incentive to invest in further research.
Future Development Pathways
With the patent now secured, Alpha Cognition is expected to explore clinical development pathways for ALPHA-1062 in traumatic brain injury. This may involve:
- Preclinical studies to further validate the mechanism of action in TBI models
- Phase 1 and Phase 2 clinical trials to assess safety and efficacy in TBI patients
- Strategic partnerships to accelerate development and commercialization
The company may also evaluate regulatory pathways, including potential expedited programs, given the high unmet need in TBI. Regulatory agencies often provide incentives for therapies targeting conditions with limited treatment options, which could further support the advancement of ALPHA-1062.
Strengthening the Pipeline and Long-Term Vision
The addition of TBI as a target indication reflects Alpha Cognition’s broader vision of building a diversified and sustainable neuroscience pipeline. By focusing on diseases with significant unmet needs, the company aims to create meaningful impact while driving long-term growth.
The synergy between ALPHA-1062 and ZUNVEYL® also highlights the company’s integrated approach to drug development. Both assets contribute to a cohesive strategy centered on addressing neurological disorders through innovative therapeutics.
As the company continues to expand its intellectual property and clinical programs, it is positioning itself as a key player in the evolving landscape of neurodegenerative and neurological disease treatment.
The issuance of U.S. Patent No. 12,589,099 marks a pivotal moment for Alpha Cognition. By securing protection for the use of ALPHA-1062 in traumatic brain injury, the company has taken a significant step toward expanding its therapeutic reach and unlocking new commercial opportunities.
This milestone underscores the versatility of ALPHA-1062, the strength of Alpha Cognition’s intellectual property strategy, and the company’s commitment to addressing critical unmet medical needs. With a large market opportunity, no existing approved therapies, and patent protection extending through 2045, the path forward presents both challenges and substantial promise.
As Alpha Cognition advances its development efforts, the potential impact of ALPHA-1062 on patients with traumatic brain injury could represent a major breakthrough in the field of neuroscience—offering hope where few treatment options currently exist.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.
This news release includes forward-looking statements within the meaning of applicable United States and Canadian securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s expectation that the additional U.S. patent will provide U.S. patent protection through July 2045 and supporting ZUNVEYL’s long-term differentiation and enhancing its commercial value and protecting key methods of administering benzgalantamine, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital, including bridge funding, to implement our plans to commercialize ZUNVEYL , risks regarding the efficacy and tolerability of ZUNVEYL , risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL , risks related to the Company’s intellectual property in relation to ZUNVEYL , risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL , risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K as filed with the SEC on March 31, 2026 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.
